ArticleCureus2025
Treatment of Refractory Grover's Disease With Dupilumab: A Case Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Chronic-Recurrent, Limb-Predominant Grover Disease in a Young Adult: A Clinicopathological Diagnostic Challenge.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Grover's disease (GD) is a pruritic skin condition characterized by erythematous, scaly papules on the trunk, often resolving spontaneously but sometimes becoming persistent and difficult to manage. In this case study, we discuss a 73-year-old male with treatment-resistant GD who experienced significant improvement with dupilumab injections. Within two weeks, the patient reported noticeable improvement in pruritus and rash, with complete resolution achieved after five months of continued treatment and no notable adverse effects. This case can highlight dupilumab as a promising option for refractory GD, as well as support the hypothesis of an immune-mediated pathogenesis of GD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.